Dr. Manoj Garg completed his PhD at the National Institute of Immunology (NII), New Delhi and University of Rajasthan, Jaipur, India. He joined as a Research Scientist at the Cancer Science Institute (CSI), National University of Singapore, Singapore in 2010 and extensively worked on cutting-edge technologies including next‐generation sequencing of both DNA and RNA, shRNA library screening, drug screening in different subtypes of Acute myeloid leukemia (AML), Acute Lymphocytic leukemia (ALL), esophageal squamous cell carcinoma, pancreatic carcinoma, anaplastic thyroid carcinoma, and liposarcoma. In 2016, Dr. Garg was awarded Ramalingaswami Fellowship and returned to India and joined as an Assistant Professor at Cancer Institute, Chennai. He received the Early Career Research Award from Science Engineering and Research Board (SERB), GOI in 2017. Dr. Garg has published his research in a range of well‐reputed scientific journals and serves as an editor for various international journal. Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer‑reviewed research and review articles in high‑impact journals, received multiple international awards, and serves on the editorial boards of more than 15 international journals. Dr. Amit Kumar Pandey completed his postdoctoral training at the Cancer Science Institute of Singapore, National University of Singapore, Singapore where he worked on exploring the role of miRNAs in epigenetic regulation of metastatic breast cancer, and Max Delbruck Center for Molecular Medicine, Berlin, Germany where he worked on exploring the role of non-coding RNAs in metabolism. Dr. Pandey has been working in the field of non-coding RNAs for the last 12 years. He has worked extensively in molecular and cell biology, cell signaling, next generation sequencing. For the last 3 years Dr. Pandey has been working as Assistant professor and running 4 research grants from various govt. agencies as principal investigator. Dr. Pandey currently serves as editor of PLOS One and review editor of Frontiers in Molecular Biosciences.

"... to uncover the details concerning how gene expression is controlled,… this book consists of 19 independently authored chapters designed to "bring our vast knowledge gene expression regulation under a single canopy." Given the near infinite dimensions of the subject at hand,… the goal of this book is to produce a relatively compact and up-to-date overview of transcriptional and translational gene regulatory mechanisms, [and] it is important to consider whether the wealth of knowledge on this topic is too vast to distill into a single volume.” --©Doody’s Review Service, 2023, Peter J. Kennelly, PhD (Virginia Tech)

• Section I: Introduction 1. Current perspectives on transcription and translational regulators in Health and diseases 2. Role of alternative splicing in health and diseasesSection II: Transcriptional and translational regulators in cancer 3. Transcriptional regulation in cancer progression 4. Role of transcriptional and post-transcriptional regulation of sphingolipid genes in molecular heterogeneity of breast cancer 5. Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy 6. CRISPR/Cas9 mediated regulation in cancer 7. Biomarkers for Diagnosis, Prognosis, Treatment of Gastro-Intestinal cancer 8. Regulation of post-transcriptional events by RNA-binding proteins 9. The language of post-translational modifications in cancers and other diseases 10. Ubiquitin proteasome system-mediated regulation of protein function and stability 11. Post-transcriptional regulations in epithelial-tomesenchymal transition and endothelial-to-mesenchymal transitionsSection III: Transcriptional and translation regulators of other diseases 12. Noncoding RNAs in Diabetes 13. MicroRNAs as epigenetic regulators for gut microbiome 14. Cross talk between miRNAs and epigenetics during braindevelopment and neurological diseases15. The role of non-coding RNAs in rheumatoid arthritis 16. Role of miRNA in autoimmune and inflammatory skin diseases 17. Current Advances in Cancer Prevention and Treatment by Natural Products 18. Therapeutic inhibition of pro-inflammatory cytokins by phytochemicals in osteoarthritis 19. Redox Signaling and Cardiovascular Disease: New Paradigms and discoveriesSection IV: Therapeutics 20. Modulation of epigenetic enzymes by natural agents 21. Inhibitors targeting epigenetic modifications in cancer 22. Drug rechanneling a new paradigm for cancer treatment

Dr. Manoj Garg completed his PhD at the National Institute of Immunology (NII), New Delhi and University of Rajasthan, Jaipur, India. He joined as a Research Scientist at the Cancer Science Institute (CSI), National University of Singapore, Singapore in 2010 and extensively worked on cutting-edge technologies including next‐generation sequencing of both DNA and RNA, shRNA library screening, drug screening in different subtypes of Acute myeloid leukemia (AML), Acute Lymphocytic leukemia (ALL), esophageal squamous cell carcinoma, pancreatic carcinoma, anaplastic thyroid carcinoma, and liposarcoma. In 2016, Dr. Garg was awarded Ramalingaswami Fellowship and returned to India and joined as an Assistant Professor at Cancer Institute, Chennai. He received the Early Career Research Award from Science Engineering and Research Board (SERB), GOI in 2017. Dr. Garg has published his research in a range of well‐reputed scientific journals and serves as an editor for various international journal. Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer‑reviewed research and review articles in high‑impact journals, received multiple international awards, and serves on the editorial boards of more than 15 international journals. Dr. Amit Kumar Pandey completed his postdoctoral training at the Cancer Science Institute of Singapore, National University of Singapore, Singapore where he worked on exploring the role of miRNAs in epigenetic regulation of metastatic breast cancer, and Max Delbruck Center for Molecular Medicine, Berlin, Germany where he worked on exploring the role of non-coding RNAs in metabolism. Dr. Pandey has been working in the field of non-coding RNAs for the last 12 years. He has worked extensively in molecular and cell biology, cell signaling, next generation sequencing. For the last 3 years Dr. Pandey has been working as Assistant professor and running 4 research grants from various govt. agencies as principal investigator. Dr. Pandey currently serves as editor of PLOS One and review editor of Frontiers in Molecular Biosciences.

"... to uncover the details concerning how gene expression is controlled,… this book consists of 19 independently authored chapters designed to "bring our vast knowledge gene expression regulation under a single canopy." Given the near infinite dimensions of the subject at hand,… the goal of this book is to produce a relatively compact and up-to-date overview of transcriptional and translational gene regulatory mechanisms, [and] it is important to consider whether the wealth of knowledge on this topic is too vast to distill into a single volume.” --©Doody’s Review Service, 2023, Peter J. Kennelly, PhD (Virginia Tech)

• Section I: Introduction 1. Current perspectives on transcription and translational regulators in Health and diseases 2. Role of alternative splicing in health and diseasesSection II: Transcriptional and translational regulators in cancer 3. Transcriptional regulation in cancer progression 4. Role of transcriptional and post-transcriptional regulation of sphingolipid genes in molecular heterogeneity of breast cancer 5. Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy 6. CRISPR/Cas9 mediated regulation in cancer 7. Biomarkers for Diagnosis, Prognosis, Treatment of Gastro-Intestinal cancer 8. Regulation of post-transcriptional events by RNA-binding proteins 9. The language of post-translational modifications in cancers and other diseases 10. Ubiquitin proteasome system-mediated regulation of protein function and stability 11. Post-transcriptional regulations in epithelial-tomesenchymal transition and endothelial-to-mesenchymal transitionsSection III: Transcriptional and translation regulators of other diseases 12. Noncoding RNAs in Diabetes 13. MicroRNAs as epigenetic regulators for gut microbiome 14. Cross talk between miRNAs and epigenetics during braindevelopment and neurological diseases15. The role of non-coding RNAs in rheumatoid arthritis 16. Role of miRNA in autoimmune and inflammatory skin diseases 17. Current Advances in Cancer Prevention and Treatment by Natural Products 18. Therapeutic inhibition of pro-inflammatory cytokins by phytochemicals in osteoarthritis 19. Redox Signaling and Cardiovascular Disease: New Paradigms and discoveriesSection IV: Therapeutics 20. Modulation of epigenetic enzymes by natural agents 21. Inhibitors targeting epigenetic modifications in cancer 22. Drug rechanneling a new paradigm for cancer treatment

Dr. Manoj Garg completed his PhD at the National Institute of Immunology (NII), New Delhi and University of Rajasthan, Jaipur, India. He joined as a Research Scientist at the Cancer Science Institute (CSI), National University of Singapore, Singapore in 2010 and extensively worked on cutting-edge technologies including next‐generation sequencing of both DNA and RNA, shRNA library screening, drug screening in different subtypes of Acute myeloid leukemia (AML), Acute Lymphocytic leukemia (ALL), esophageal squamous cell carcinoma, pancreatic carcinoma, anaplastic thyroid carcinoma, and liposarcoma. In 2016, Dr. Garg was awarded Ramalingaswami Fellowship and returned to India and joined as an Assistant Professor at Cancer Institute, Chennai. He received the Early Career Research Award from Science Engineering and Research Board (SERB), GOI in 2017. Dr. Garg has published his research in a range of well‐reputed scientific journals and serves as an editor for various international journal. Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer‑reviewed research and review articles in high‑impact journals, received multiple international awards, and serves on the editorial boards of more than 15 international journals. Dr. Amit Kumar Pandey completed his postdoctoral training at the Cancer Science Institute of Singapore, National University of Singapore, Singapore where he worked on exploring the role of miRNAs in epigenetic regulation of metastatic breast cancer, and Max Delbruck Center for Molecular Medicine, Berlin, Germany where he worked on exploring the role of non-coding RNAs in metabolism. Dr. Pandey has been working in the field of non-coding RNAs for the last 12 years. He has worked extensively in molecular and cell biology, cell signaling, next generation sequencing. For the last 3 years Dr. Pandey has been working as Assistant professor and running 4 research grants from various govt. agencies as principal investigator. Dr. Pandey currently serves as editor of PLOS One and review editor of Frontiers in Molecular Biosciences.

"... to uncover the details concerning how gene expression is controlled,… this book consists of 19 independently authored chapters designed to "bring our vast knowledge gene expression regulation under a single canopy." Given the near infinite dimensions of the subject at hand,… the goal of this book is to produce a relatively compact and up-to-date overview of transcriptional and translational gene regulatory mechanisms, [and] it is important to consider whether the wealth of knowledge on this topic is too vast to distill into a single volume.” --©Doody’s Review Service, 2023, Peter J. Kennelly, PhD (Virginia Tech)

• Section I: Introduction 1. Current perspectives on transcription and translational regulators in Health and diseases 2. Role of alternative splicing in health and diseasesSection II: Transcriptional and translational regulators in cancer 3. Transcriptional regulation in cancer progression 4. Role of transcriptional and post-transcriptional regulation of sphingolipid genes in molecular heterogeneity of breast cancer 5. Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy 6. CRISPR/Cas9 mediated regulation in cancer 7. Biomarkers for Diagnosis, Prognosis, Treatment of Gastro-Intestinal cancer 8. Regulation of post-transcriptional events by RNA-binding proteins 9. The language of post-translational modifications in cancers and other diseases 10. Ubiquitin proteasome system-mediated regulation of protein function and stability 11. Post-transcriptional regulations in epithelial-tomesenchymal transition and endothelial-to-mesenchymal transitionsSection III: Transcriptional and translation regulators of other diseases 12. Noncoding RNAs in Diabetes 13. MicroRNAs as epigenetic regulators for gut microbiome 14. Cross talk between miRNAs and epigenetics during braindevelopment and neurological diseases15. The role of non-coding RNAs in rheumatoid arthritis 16. Role of miRNA in autoimmune and inflammatory skin diseases 17. Current Advances in Cancer Prevention and Treatment by Natural Products 18. Therapeutic inhibition of pro-inflammatory cytokins by phytochemicals in osteoarthritis 19. Redox Signaling and Cardiovascular Disease: New Paradigms and discoveriesSection IV: Therapeutics 20. Modulation of epigenetic enzymes by natural agents 21. Inhibitors targeting epigenetic modifications in cancer 22. Drug rechanneling a new paradigm for cancer treatment